Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis

Published:2018-09-20 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Manova Manoela,Savova Alexandra,Vasileva Maria,Terezova Silvia,Kamusheva Maria,Grekova Daniela,Petkova Valentina,Petrova Guenka

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference36 articles.

1. Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative.;Aletaha;Arthritis Rheum.,2010

2. Innovation and competition: will biosimilars succeed?;Blackstone;Biotechnol. Healthc.,2012

3. The economics of biosimilars.;Blackstone;Am. Health Drug Benefits,2013

4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.;Chen;Health Technol. Assess.,2006

5. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis.;Chiou;Expert Rev. Pharmacoecon. Outcomes Res.,2004

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis;Cells;2024-07-30

2. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012–19;PLOS ONE;2024-06-06

3. Deep Learning Enabled Whale Optimization Algorithm for Accurate Prediction of RA Disease;Salud, Ciencia y Tecnología - Serie de Conferencias;2024-03-11

4. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia;Journal of Medical Economics;2024-01

5. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?;Expert Review of Pharmacoeconomics & Outcomes Research;2023-07-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3